Holobiome is a private biotechnology company developing microbiome-based therapeutics for diseases of the central and enteric nervous systems. On the cellular level, humans are as much microbe as human, and for each human cell there is at least one bacterial cell either on our skin or inside of us. This enormous community of bacteria is our microbiome, and it influences many components of human health, such as metabolism, susceptibility to disease, and the immune response. Remarkably, recent evidence, including that of the founding and scientific teams, suggest the microbiome influences diseases of the nervous system. The lead products of Holobiome consist of naturally occurring bacteria that modulate host neurotransmission, which will have broad therapeutic utility.
